Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.

19 May 2011

Mitomics enters licensing agreement with QDx Pathology Services for QPredict Prostate Mitomic Test

Mitomics, world leader in the research and development of mitochondrial genome-based products, today announced it has entered into a non-exclusive licensing agreement with QDx Pathology Services to develop, market and process the QPredict™ Prostate Mitomic Test.

19 May 2011

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax Phase II adjuvant breast cancer clinical trial at the 2011 annual meeting of The American Society of Clinical Oncology in Chicago.

19 May 2011

AstraZeneca announces encouraging results from olaparib phase II study in serous ovarian cancer

AstraZeneca announced today encouraging results from a phase II study in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) who had received maintenance treatment with the investigational drug olaparib, after the completion of chemotherapy.

19 May 2011

YM BioSciences announces updated interim results from CYT387 Phase I/II trial in myelofibrosis

YM BioSciences Inc., today reported updated interim results for the first 60 patients with high/intermediate-risk myelofibrosis who have completed a minimum of three cycles of treatment (12 weeks) in its ongoing Phase I/II multi-center study.

19 May 2011

Study: 10% of cancer patients fail to fill initial oral oncolytic prescriptions

Ten percent of cancer patients failed to fill their initial prescriptions for oral anti-cancer drugs, according to a new study published jointly today in the Journal of Oncology Practice and American Journal of Managed Care.

19 May 2011

Simple lymphocyte count effectively identifies prognosis of renal cell carcinoma

Each year, kidney cancer is diagnosed in nearly 60,000 people in the U.S. Many of these patients undergo surgery to remove the affected kidney, but this procedure can be risky for the elderly and those who have other health problems. Unfortunately, the prognosis of kidney cancer patients often cannot be determined until tumor samples are surgically removed and evaluated.

19 May 2011

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.

19 May 2011

APP receives FDA approval to market Gemcitabine HCI for Injection, USP in 2 g dosage

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Gemcitabine HCI for Injection, USP, in the 2 g dosage strength. APP will launch this presentation of Gemcitabine immediately.

19 May 2011

New breast cancer biomarker may help identify women's response to tamoxifen

Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy.

19 May 2011

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma, axitinib significantly extended progression-free survival at the 47th Annual American Society of Clinical Oncology meeting in Chicago from June 3-7, 2011.

19 May 2011

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to new research from The University of Texas MD Anderson Cancer Center.

19 May 2011

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.

19 May 2011

Heavy alcohol consumption linked to increased risk of gastric cancer

The results from a very well-done meta-analysis support other data generated on the risk of alcohol consumption and gastric cancer - that is - that the risk may be real for heavy alcohol consumption but not for moderate intake.

19 May 2011

Mpex, Synteract partner for cystic fibrosis fundraising event

Synteract, Inc., a full-service, global contract research organization, and Mpex Pharmaceuticals, a biopharmaceutical company developing new therapies to combat the growing issue of antibiotic resistance, have partnered for the second annual Great Strides fundraiser to benefit cystic fibrosis.

19 May 2011

OctreoPharm Sciences granted SME status by the EMA

OctreoPharm Sciences GmbH, a medicine developer and specialist for radioactive labeled contrast agents in nuclear medicine has been granted SME status as small-sized enterprise in research and development by the European Medicine Agency EMA.

18 May 2011

MDxHealth reduces first quarter net loss by 17%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the quarter ended March 31, 2011.

18 May 2011

Clinical PET system for early stage breast cancer diagnosis

European researchers have developed a clinical PET system with the highest resolution and sensitivity in the market, specifically dedicated to breast cancer detection in early stages.

18 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

Aeterna Zentaris first quarter revenues increase to $7.4 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the first quarter ended March 31, 2011.

18 May 2011

Oncology News and Research

Further Reading

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Mitomics enters licensing agreement with QDx Pathology Services for QPredict Prostate Mitomic Test

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

AstraZeneca announces encouraging results from olaparib phase II study in serous ovarian cancer

YM BioSciences announces updated interim results from CYT387 Phase I/II trial in myelofibrosis

Study: 10% of cancer patients fail to fill initial oral oncolytic prescriptions

Simple lymphocyte count effectively identifies prognosis of renal cell carcinoma

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

APP receives FDA approval to market Gemcitabine HCI for Injection, USP in 2 g dosage

New breast cancer biomarker may help identify women's response to tamoxifen

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Heavy alcohol consumption linked to increased risk of gastric cancer

Mpex, Synteract partner for cystic fibrosis fundraising event

OctreoPharm Sciences granted SME status by the EMA

MDxHealth reduces first quarter net loss by 17%

Clinical PET system for early stage breast cancer diagnosis

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Aeterna Zentaris first quarter revenues increase to $7.4 million

Industry Focus eBook - Oncology (3rd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News